Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carvedilol controlled release + lisinopril
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carvedilol controlled release (CR) plus lisinopril is a fixed-dose combination therapy used primarily for the management of hypertension and heart failure. Carvedilol is a non-selective beta-adrenergic antagonist with additional alpha-1 adrenergic blocking activity, leading to decreased heart rate, reduced myocardial contractility, and vasodilation. Lisinopril is an angiotensin-converting enzyme inhibitor (ACEI) that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation and reduced aldosterone-mediated volume expansion. The combination targets multiple pathways involved in blood pressure regulation and cardiac remodeling. Clinical studies have shown that this combination can improve endothelial function and reduce oxidative stress in patients with hypertension or heart failure[1][2]. Both drugs are well-established therapies individually; their combined use aims to achieve better blood pressure control and cardiovascular protection than monotherapy.
- Brand names
- Coreg CR + ZestrilCoreg CR + Prinivil
- Other names
- carvedilol CR + lisinoprilextended-release carvedilol + lisinopril
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ACE (Angiotensin Converting Enzyme)DRD2 (Dopamine D2 Receptor)ADRA1A (α1A)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on carvedilol controlled release + lisinopril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carvedilol controlled release + lisinopril.